Quantcast

Industry news that matters to you.  Learn more

PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules

PDI, Inc. (Nasdaq: PDII) recently announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.  Over 525,000 thyroid FNA’s (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate.  ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.

Cardiac Biomarker ST2 Proves Far Superior To Galectin-3 In A Head-to-Head Study

Critical Diagnostics recently announced that the study, “Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3”, recently published online in JACC (the Journal of the American College of Cardiology) comparing the company’s novel cardiac biomarker ST2 to Galectin-3 (Gal-3), a biomarker from BG Medicine (NASDAQ: BGMD), found ST2 to be superior.

Lifestyle, Age Linked to Diabetes-related Protein

Over the last decade researchers have amassed increasing evidence that relatively low levels of a protein called sex hormone binding globulin (SHBG) can indicate an elevated risk of type 2 diabetes and metabolic syndrome years in advance.

Independent Study: Health Diagnostic Laboratory, Inc. Services Lead to Cost Savings of 23% and Significantly Improved Health Outcomes After Two Years

Advanced cardiometabolic testing paired with follow-up health management from Health Diagnostic Laboratory, Inc. has resulted in a 23 percent decrease in a patient’s overall healthcare costs and an improved lipid profile in just two years, according to a new independent study published recently in Population Health Management.

Article Highlights the Value of PreDx Testing of Prediabetic Patients in the Primary Care Setting

An article published in Clinical Diabetes describes the clinical value of PreDx testing for more effective management of prediabetes patients in the primary care practice setting. The PreDx test is a predictive multi-biomarker fasting blood test developed by Tethys Bioscience, Inc., that stratifies adult patients with prediabetes into low, moderate or high risk categories for developing type 2 diabetes within 5 years. In addition to enabling the more cost‐efficient allocation of healthcare resources toward those prediabetes patients at highest risk of progression, PreDx has also been shown to be an effective tool for monitoring the impact of lifestyle interventions in reducing the likelihood of developing the disease.

Authored by primary care practitioners Paul Rich, MD and Charles Shaefer, MD, endocrinologist Steven Edelman, MD, and Chris G. Parkin, MS, the article discusses how PreDx testing helps health care providers overcome two important obstacles that hinder more effective diabetes prevention efforts in the primary care setting – the inability of current assessment tools to differentiate prediabetes patients based on risk of progression, and the constraints on physician time and resources. A review of published literature regarding the clinical validity of PreDx for the risk-based stratification of prediabetes patients and the monitoring of their response to interventions is accompanied by case studies that illustrate the authors’ experiences with the test in their practices, and concludes with a four-step process to help clinicians effectively integrate the PreDx test into their prediabetes management protocols.

The authors summarized their experiences with PreDx testing as follows:

Paul Rich, MD: “Our experience with PreDx testing has illustrated its value as a practical means to achieve greater success in diabetes prevention at the primary care level. Unlike other lab tests that give us more numbers to consider, PreDx interprets those results for us, generating a predictive score that identifies our most vulnerable prediabetes patients, and helps guide our management strategies for those patients. That saves us time, optimizes how we use our resources, and gives our patients a better chance of avoiding a very bad disease. No other test does that.”

Charles Shaefer, MD: “The insights we get with PreDx, in terms of who to treat more intensively and how well they’re responding to those interventions, have enabled us to make more-informed treatment decisions that produce better outcomes, as demonstrated by the results achieved in our case studies.”

Steven Edelman, MD: “An added advantage of PreDx is the motivational impact their score has on patients who have resisted dealing with their diabetes risk despite previous warnings. Somehow, a personalized numerical score, that presents their risk on a scale of 1 to 10, gets through to them, and prompts them to take action to lower their risk by making healthier lifestyle choices.”

Juan Frias, MD, Chief Medical Officer for Tethys Bioscience and a practicing endocrinologist, commented on how the review article could help enhance the use of the PreDx test, especially given the recent launch of a fingerstick option for blood collection. “PreDx is a valuable clinical tool that, until recently, has only been accessible to practices with in-practice phlebotomy capabilities. The flexibility to perform the test with either venous or capillary blood means that many more practices will be able to offer PreDx to their prediabetes patients, and benefit from the unique clinical utilities it offers.”

Study: Using a Quantitative Measure of Diabetes Risk in Clinical Practice to Target and Maximize Diabetes Prevention Interventions

Source: PR Newswire